BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Henan Genuine Biotech readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Henan Genuine Biotech's drugs run
 \, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07308782-1025@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:CL-197: Phase 2 readout est. (NCT07308782)
DESCRIPTION:CL-197\, phase 2\, HIV.\nStudy: A Phase Ⅱa Clinical Study of 
 CL-197 Capsules\nEstimated primary completion: December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/cl-197#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07308782
URL:https://assetmemo.bio/drug/cl-197#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07362940-2458@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Dositinib mesylate: Phase 1/2 readout est. (NCT07362940)
DESCRIPTION:Dositinib mesylate\, phase 1/2\, Non-Small Cell Lung Cancer.\nS
 tudy: A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dosit
 inib\nEstimated primary completion: 31 July 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/dositinib-mesylate#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07362940
URL:https://assetmemo.bio/drug/dositinib-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07231068-2458@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dositinib mesylate: Phase 1/2 readout est. (NCT07231068)
DESCRIPTION:Dositinib mesylate\, phase 1/2\, Non-Small Cell Lung Cancer.\nS
 tudy: A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study
  of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advan
 ced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation\n
 Estimated primary completion: 31 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/dositinib-mesylate#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07231068
URL:https://assetmemo.bio/drug/dositinib-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
